BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 8146893)

  • 1. Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients.
    Friedberg RC; Donnelly SF; Mintz PD
    Transfusion; 1994 Mar; 34(3):215-20. PubMed ID: 8146893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet crossmatch testing for donor selection.
    Slichter SJ
    Prog Clin Biol Res; 1982; 88():153-64. PubMed ID: 7100207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
    Heal JM; Blumberg N; Masel D
    Blood; 1987 Jul; 70(1):23-30. PubMed ID: 3474041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet crossmatching. A direct approach to the selection of platelet transfusions for the alloimmunized thrombocytopenic patient.
    Kickler TS; Ness PM; Braine HG
    Am J Clin Pathol; 1988 Jul; 90(1):69-72. PubMed ID: 3389345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets.
    Gelb AB; Leavitt AD
    Transfusion; 1997 Jun; 37(6):624-30. PubMed ID: 9191823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients.
    Freedman J; Gafni A; Garvey MB; Blanchette V
    Transfusion; 1989; 29(3):201-7. PubMed ID: 2493693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet crossmatching with lymphocytotoxicity test: an effective method in alloimmunized Chinese patients.
    Chow MP; Yung CH; Hu HY; Tzeng JL; Lin WM; Lin CK
    Transfusion; 1991 Sep; 31(7):595-9. PubMed ID: 1891789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions.
    Sintnicolaas K; Löwenberg B
    Br J Haematol; 1996 Mar; 92(4):1005-10. PubMed ID: 8616059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity.
    Petz LD; Garratty G; Calhoun L; Clark BD; Terasaki PI; Gresens C; Gornbein JA; Landaw EM; Smith R; Cecka JM
    Transfusion; 2000 Dec; 40(12):1446-56. PubMed ID: 11134563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful management of alloimmunized patients by transfusing HLA compatible and crossmatched platelets.
    Yung CH; Chow MP; Hu HY; Tzeng JL; Mou LL; Deng JM
    Zhonghua Yi Xue Za Zhi (Taipei); 1991 Apr; 47(4):228-36. PubMed ID: 1646671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet transfusion therapy in an alloimmunized patient. The value of crossmatch procedures for donor selection.
    Hecht T; Wolf JL; Mraz L; Scott EP; Patz LD
    JAMA; 1982 Nov; 248(18):2301-3. PubMed ID: 6752444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
    Wiita AP; Nambiar A
    Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet crossmatches of single-donor platelet concentrates using a latex agglutination assay.
    Ogden DM; Asfour A; Koller C; Lichtiger B
    Transfusion; 1993 Aug; 33(8):644-50. PubMed ID: 8342230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive value of crossmatching platelet transfusion for alloimmunized patients.
    Kickler TS; Braine H; Ness PM
    Transfusion; 1985; 25(4):385-9. PubMed ID: 4024239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates.
    O'Connell BA; Lee EJ; Rothko K; Hussein MA; Schiffer CA
    Blood; 1992 Jan; 79(2):527-31. PubMed ID: 1730095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing.
    Rachel JM; Summers TC; Sinor LT; Plapp FV
    Am J Clin Pathol; 1988 Jul; 90(1):63-8. PubMed ID: 3389344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
    Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of in vitro assays in selection of compatible platelet donors.
    Tosato G; Appelbaum FR; Trapani RJ; Dowling R; Deisseroth AB
    Transfusion; 1980; 20(1):47-54. PubMed ID: 7355471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to random apheresis platelets versus HLA-selected platelets versus pooled platelets in HLA-sensitized patients.
    Gavva C; Barroso J; Gernsheimer T; Metcalf RA; Warner P; Pagano MB
    Transfusion; 2019 Jul; 59(7):2276-2281. PubMed ID: 31032968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial.
    Marsh JC; Stanworth SJ; Pankhurst LA; Kallon D; Gilbertson AZ; Pigden C; Deary AJ; Mora AS; Brown J; Laing ES; Choo LL; Hodge R; Llewelyn CA; Harding K; Sage D; Mijovic A; Mufti GJ; Navarrete CV; Brown CJ
    Blood; 2021 Jan; 137(3):310-322. PubMed ID: 33475737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.